---
title: "Weekly Recap | Compass Therapeutics -40.53%, FDA pushes survival-benefit trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/300187366.md"
description: "Compass Therapeutics (CMPX) fell 40.53% this week to close at $1.13, while the S&P 500 gained 1.21%, leaving the stock roughly 41.74 percentage points behind the benchmark. The week opened at $1.88 on Monday and turned lower almost immediately. Tuesday saw volume spike to 27.2 million shares and a sharp decline, followed by three more days of weakness. The stock touched a low of $1.10 on Thursday and finished Friday at $1.13, with weekly amplitude of 41.49%."
datetime: "2026-09-26T06:10:34.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/300187366.md)
  - [en](https://longbridge.com/en/news/300187366.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/300187366.md)
generator: "portal-rs"
---

# Weekly Recap | Compass Therapeutics -40.53%, FDA pushes survival-benefit trial

## The Week

Compass Therapeutics (CMPX) fell 40.53% this week to close at $1.13, while the S&P 500 gained 1.21%, leaving the stock roughly 41.74 percentage points behind the benchmark. The week opened at $1.88 on Monday and turned lower almost immediately. Tuesday saw volume spike to 27.2 million shares and a sharp decline, followed by three more days of weakness. The stock touched a low of $1.10 on Thursday and finished Friday at $1.13, with weekly amplitude of 41.49%.

## Key Events

After Tuesday’s close, the company said the FDA has urged it to run a survival-benefit trial before submitting the biologics licence application for tovecimig in biliary tract cancer. The stock sold off on Tuesday and Wednesday. Several brokers then adjusted their views: LifeSci Capital downgraded the name to hold, Wedbush cut it to neutral with a $1 target, while Citizens maintained its market outperform rating and a $4 target. On Friday, chief accounting officer Neil Lerner bought 2,500 common shares worth $2,850.

## Analyst Ratings

Fifteen firms cover the stock: 10 rate it buy, 2 rate it outperform and 3 rate it hold, with no underperform or sell ratings. The consensus rating is buy, with a consensus target of $5.50, about 386.7% above the latest price. Individual targets range from $1 to $12, reflecting a wide spread. The stock ranks 52nd among 506 names in the biotechnology industry.

## The Week Ahead

There are no company earnings on next week’s calendar. Macro data will be in focus: the Dallas Fed manufacturing activity index on Monday, FHFA house prices and Case Shiller indices on Tuesday, along with JOLTS job openings and consumer confidence. The key stock-specific thread remains any follow-up on the FDA’s survival-benefit trial request for tovecimig.

## In Short

The sharp weekly pullback coincided with a higher regulatory bar for the lead asset, while the ratings mix still leans buy and the consensus target sits above spot. On the latest trading day, large orders were net buyers while small and medium orders were net sellers. The next signal to watch is whether the company lays out a path for the survival-benefit trial.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [CMPX.US](https://longbridge.com/en/quote/CMPX.US.md)

## Related News & Research

- [Top Executive Quietly Boosts Stake in Emerging Biotech Player](https://longbridge.com/en/news/300836513.md)
- [Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer Drug](https://longbridge.com/en/news/299801321.md)
- [Compass Therapeutics says FDA urges survival-benefit trial before tovecimig BLA in biliary tract cancer](https://longbridge.com/en/news/299767098.md)
- [ON Semiconductor Group President Sudhir Gopalswamy disposes of 15,578 common shares for $1,246,240](https://longbridge.com/en/news/300826639.md)
- [SEALSQ Boosts Stake in WISeSat.Space as SPAC Merger Closes and Nasdaq Trading Begins](https://longbridge.com/en/news/300831795.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**